Collegium Pharmaceutical Inc Market Cap ($752.34 Million)
Market Cap & Net Worth: Collegium Pharmaceutical Inc (COLL)
Collegium Pharmaceutical Inc market cap. Collegium Pharmaceutical Inc (NASDAQ:COLL) has a market capitalization of $752.34 Million ($752.34 Million) as of November 1, 2026. Listed on the NASDAQ stock exchange, this USA-based company holds position #9811 globally and #2709 in its home market, demonstrating a 1.28% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Collegium Pharmaceutical Inc's stock price $23.80 by its total outstanding shares 31610976 (31.61 Million). Also see Collegium Pharmaceutical Inc (COLL) cash flow conversion for how efficiently the company converts equity into cash flow.
Collegium Pharmaceutical Inc Market Cap History (2015–2026)
Collegium Pharmaceutical Inc market cap history from 2015 to 2026. Data shows growth from $869.30 Million to $752.34 Million (2.02% CAGR). Check current stock price of Collegium Pharmaceutical Inc for real-time trading data and today's change.
Index Memberships
Collegium Pharmaceutical Inc is a constituent of 4 market indices:
| Index | Total Market Cap | Weight (%) | Rank by Market Cap |
|---|---|---|---|
|
NASDAQ Health Care
IXHC
|
$2.62 Trillion | 0.03% | #282 of 976 |
|
NASDAQ Composite
IXIC
|
$40.09 Trillion | 0.00% | #1041 of 3165 |
|
NASDAQ Biotechnology
NBI
|
$1.84 Trillion | 0.04% | #165 of 263 |
|
S&P Small-Cap 600 Index
SML
|
$1.56 Trillion | 0.07% | #509 of 602 |
Weight: Collegium Pharmaceutical Inc's market cap as a percentage of total index value. Rank: Position among all constituents by market cap.
Collegium Pharmaceutical Inc Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Collegium Pharmaceutical Inc's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance. Explore Collegium Pharmaceutical Inc net asset momentum to track how rapidly the company is growing its equity base year over year.
Latest Price to Sales (P/S) Ratio
1.43x
Collegium Pharmaceutical Inc's market cap is 1.43 times its annual revenue
Latest Price to Earnings (P/E) Ratio
13.09x
Collegium Pharmaceutical Inc's market cap is 13.09 times its annual earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2016 | $492.18 Million | $1.71 Million | -$94.18 Million | 287.66x | N/A |
| 2017 | $583.54 Million | $28.48 Million | -$74.86 Million | 20.49x | N/A |
| 2018 | $542.76 Million | $280.41 Million | -$39.13 Million | 1.94x | N/A |
| 2019 | $650.55 Million | $296.70 Million | -$22.72 Million | 2.19x | N/A |
| 2020 | $633.17 Million | $310.02 Million | $26.75 Million | 2.04x | 23.67x |
| 2021 | $590.49 Million | $276.87 Million | $71.52 Million | 2.13x | 8.26x |
| 2022 | $733.37 Million | $463.93 Million | -$25.00 Million | 1.58x | N/A |
| 2023 | $972.99 Million | $566.77 Million | $48.16 Million | 1.72x | 20.21x |
| 2024 | $905.65 Million | $631.45 Million | $69.19 Million | 1.43x | 13.09x |
Competitor Companies of COLL by Market Capitalization
Companies near Collegium Pharmaceutical Inc in the global market cap rankings as of November 1, 2026. Also see Collegium Pharmaceutical Inc assets under control for a full breakdown of the balance sheet.
Key companies related to Collegium Pharmaceutical Inc by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #511 globally with a market cap of $52.60 Billion USD.
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #535 globally with a market cap of $50.42 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #593 globally with a market cap of $45.23 Billion USD ( CN¥309.13 Billion CNY).
- Takeda Pharmaceutical Company Limited (F:TKDA): Ranked #619 globally with a market cap of $43.60 Billion USD ( €37.29 Billion EUR).
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #511 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #535 | GALDERMA GROUP AG | NYSE:GALDY | $50.42 Billion | $46.62 |
| #593 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $45.23 Billion | CN¥48.46 |
| #619 | Takeda Pharmaceutical Company Limited | F:TKDA | $43.60 Billion | €18.30 |
Market Capitalization of Collegium Pharmaceutical Inc (2015–2026)
Market capitalization of Collegium Pharmaceutical Inc from 2015 to today. Between 2015 and today, Collegium Pharmaceutical Inc's market cap moved from $869.30 Million to $ 752.34 Million, with a yearly change of 2.02%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | $752.34 Million | -48.60% |
| 2025 | $1.46 Billion | +61.61% |
| 2024 | $905.65 Million | -6.92% |
| 2023 | $972.99 Million | +32.67% |
| 2022 | $733.37 Million | +24.20% |
| 2021 | $590.49 Million | -6.74% |
| 2020 | $633.17 Million | -2.67% |
| 2019 | $650.55 Million | +19.86% |
| 2018 | $542.76 Million | -6.99% |
| 2017 | $583.54 Million | +18.56% |
| 2016 | $492.18 Million | -43.38% |
| 2015 | $869.30 Million | -- |
End of Day Market Cap According to Different Sources
On Oct 31st, 2026 the market cap of Collegium Pharmaceutical Inc was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $752.34 Million USD |
| MoneyControl | $752.34 Million USD |
| MarketWatch | $752.34 Million USD |
| marketcap.company | $752.34 Million USD |
| Reuters | $752.34 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Collegium Pharmaceutical Inc
Collegium Pharmaceutical, Inc., a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. The company's portfolio includes Jornay PM, a central nervous system stimulant prescription medicine that contains methylphenidate HCl for the treatment of attention deficit hyperactivity disorder; Belbuca, a buccal film that contains buprenorphine… Read more